How effective are the usual treatments for ulcerative colitis?

被引:50
作者
Bebb, JR [1 ]
Scott, BB [1 ]
机构
[1] Lincoln Cty Hosp, Dept Gastroenterol, Lincoln LN2 5QY, England
关键词
D O I
10.1111/j.1365-2036.2004.02018.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Details of the efficacy of the drugs used in ulcerative colitis are not readily available. Methods: We have reviewed all placebo-controlled trials of the commonly used drugs for both induction and maintenance of remission to determine the efficacy and to calculate the numbers needed to treat (NNTs) to achieve a specified benefit for each drug. Results: The drug response rates and the NNTs (with 95% CI) are tabulated for each drug. Conclusion: Corticosteroids give a remission rate of 68% in mild or moderate disease and an NNT for remission of 2 (95% CI 1.4-5) in mild disease. Intravenous hydrocortisone gives a remission rate of 60-73%. Aminosalicylates are relatively ineffective in inducing remission with an NNT of 10 (95% CI 7-21) improving to 8 (95% CI 5-20) if the dose greater than or equal to3 g daily. They are better at maintenance (NNT = 6; 95% CI 4-8). Intravenous ciclosporin is very effective in achieving remission in severe colitis with an NNT of 1.2 (95% CI 1-2.5). Although there is fairly good evidence that azathioprine is effective in maintaining remission and is used widely, there are no suitable placebo-controlled trials to calculate the NNT.
引用
收藏
页码:143 / 149
页数:7
相关论文
共 40 条
[1]  
[Anonymous], CANADIAN J GASTROENT
[2]  
BANKS BM, 1957, GASTROENTEROLOGY, V32, P983
[3]  
BARON JH, 1962, BRIT MED J, P441
[4]   Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis [J].
D'Haens, G ;
Lemmens, L ;
Geboes, K ;
Vandeputte, L ;
Van Acker, F ;
Mortelmans, L ;
Peeters, M ;
Vermeire, S ;
Penninckx, F ;
Nevens, F ;
Hiele, M ;
Rutgeerts, P .
GASTROENTEROLOGY, 2001, 120 (06) :1323-1329
[5]   CONTROLLED THERAPEUTIC TRIAL OF LONG-TERM MAINTENANCE TREATMENT OF ULCERATIVE-COLITIS WITH SULFASALAZINE (SALAZOPYRIN) [J].
DISSANAYAKE, AS ;
TRUELOVE, SC .
GUT, 1973, 14 (12) :923-926
[6]  
DYER O, 2003, BMJ-BRIT MED J, V327, P1366
[7]   Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease [J].
Eaden, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 :15-21
[8]   COURSE AND PROGNOSIS OF ULCERATIVE COLITIS [J].
EDWARDS, FC ;
TRUELOVE, SC .
GUT, 1963, 4 (04) :299-+
[9]   OLSALAZINE VERSUS PLACEBO IN THE TREATMENT OF MILD TO MODERATE ULCERATIVE-COLITIS - A RANDOMIZED DOUBLE-BLIND TRIAL [J].
FEURLE, GE ;
THEUER, D ;
VELASCO, S ;
BARRY, BA ;
WORDEHOFF, D ;
SOMMER, A ;
JANTSCHEK, G ;
KRUIS, W .
GUT, 1989, 30 (10) :1354-1361
[10]  
HANAUER S, 1993, AM J GASTROENTEROL, V88, P1188